IHH Healthcare registered a net profit of $573m (RM$1.9b) in year-to-date (YTD) 2024, dropping 13% year-on-year (YoY).
The decrease was due to a high base last year, which recorded one-off gains of $263m (RM873.0m) from the sale of International Medical University (IMU). Excluding exceptional items, net profit grew by 35%.
Revenue and EBITDA for the period posted double-digit growth of 13% and 12%, respectively, reaching $5.3b (RM17.7b) and $1.2b (RM4.0b). The growth was driven by sustained increases in patient volumes and revenue intensity across all markets.
For Q3 2024, IHH Healthcare achieved a 73% occupancy rate, with 232,071 patient admissions across 12,220 operational beds.
In the next five years, the group intends to add approximately 4,000 new beds under its “Align-Challenge-Empower” (ACE) framework.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。